Gulf Pharmaceutical Industries a.k.a. Julphar announced that it would build the Africa’s largest injectable medicine producing facility in Ethiopia with an investment outlay of USD 50 million. Julphar has found Ethiopia to be the hub of Africa and a center for many other international organizations. The industry started operations in Ethiopia in 2012 after building a pharmaceutical plant in Addis Ababa around Jackross area with a capital outlay of USD 9.17 million. The factory became operation in 2013 producing assortments of pharmaceuticals.
According to Hassan Jibreel (Eng.)- Senior Director of Corporate Development for the company, “At the beginning, it was like coming into a black box for us to move on such a big investment in Ethiopia. But, it turned out to be very different. He stated that the second phase of this expansion project mainly consists of injectable medicine producing plants and warehouse facilities which can be considered to be the largest for the company outside of the UAE and the biggest of its kind in Africa. The injectable plant is expected to fill the demand for insulin for patients with diabetes across the country and the African continent. The company has however expressed its desire to carry out a number of conferences and workshop in order to assist local pharmaceutical manufacturers.
Julphar organized a two-day workshop in collaboration with the Ethiopian Pharmaceutical Associations (EPA) and other partners to impart standard manufacturing practices to the local industries. The workshop laid emphasis on basic pharmaceutical manufacturing practices and equipment specialized in granulation process and tablet coating.
“To realize its vision and mission, EPA is proactively forging strategic partnerships with key stakeholders and EPA is happy to have Julphar Ethiopia as one of its strategic partners,” Teferi Gedif (MPH, PhD), president of EPA, said on the occasion.